Immunotherapy inside the cell: the new frontier of cancer therapy
Frost & Sullivan Partner Dorman Followwill comments on one of the disrupting forces that are transforming the healthcare markets.
Healthcare, the world’s largest industry, is more than three times the size and value of the financial services sector, and is transforming faster than ever before, driving humanity to rethink the way we approach our health.
Immunotherapy inside the cell is one of the disrupting forces that are shaking the healthcare markets. Frost & Sullivan Senior Partner Dorman Followwill strongly believes that this is the new frontier of cancer therapy: "Immunotherapy inside the cell could be the 'Holy Grail' of cancer treatment and this is making us shift the focus from therapy to cure."
Mr Followwill who was recently quoted in an article published by the authoritative and prestigious "The Life Sciences Report" explains why some companies are leading the way in biotech by looking at how penetrate the cell membrane.
"Cancer cells tend not to be red-flagged by the immune system, but autologous (generated within the patient's body) immunotherapy would unmask the cells so that the immune system could then attack," Followwill explains. "The Holy Grail in oncology therapeutics is to find a way to trigger the body's own immune responses against cancer cells wherever they happen to be presenting."
Sorrento Therapeutics is one of the companies Frost & Sullivan has been watching closely as the Transformational Health team have been looking at the monoclonal antibody field for a long time.
Reflecting on a 2013 visit to the company's headquarters in San Diego, he noted Sorrento had a "full pipeline of oncology candidates. It was really impressive to me. And it had achieved that with a mere 18 employees." That kind of "frugal innovation," which is badly needed by big pharma, sets the company up for continued success, he said.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance